Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADEX
PACTR202402557039838Phase 2Recruiting
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dexamethasone and ribavirin in Lassa fever (2 arms), sponsored by Bernhard Nocht Institute for Tropical Medicine. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Jan 2024; status: recruiting.
02
Drugs
dexamethasoneribavirin
03
Conditions
Lassa fever
Beyond the preview
Go deeper on PACTR202402557039838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202402557039838.